{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:33:55Z","timestamp":1787758435629,"version":"build-2784847793"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Adenomyosis is defined as the invasion of the basal endometrium (stroma and glands) into the underlying myometrium. It may lead to abnormal uterine bleeding (AUB), pelvic pain, and infertility. The definitive treatment is hysterectomy. Some conservative measures have been used in patients willing to procreate. Ulipristal acetate is a selective progesterone receptor modulator used to treat AUB caused by leiomyomas. This is a systematic review on the use of ulipristal to treat adenomyosis. Eight eligible articles were retrieved from PubMed, SCOPUS, and Cochrane Library. Only one randomized clinical trial was published until date concerning this matter. It seems that ulipristal acetate induces partial or complete remission of AUB caused by adenomyosis, but the evidence concerning its effect on pelvic pain and the radiologic findings of the disease is conflicting. Nevertheless, given the paucity of data, it is still preliminary to draw any conclusion about the subject.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/gmit.gmit_95_21","type":"journal-article","created":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T09:56:53Z","timestamp":1665050213000},"page":"198-202","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Ulipristal Acetate in Adenomyosis"],"prefix":"10.4103","volume":"11","author":[{"given":"Manuel","family":"Gon\u00e7alves-Henriques","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ant\u00f3nio","family":"de Pinho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00edlia","family":"Freixo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Liz-Coelho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Ceschin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Brand\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20240830","doi-asserted-by":"crossref","first-page":"E242","DOI":"10.1503\/cmaj.201607","article-title":"Diagnosis and treatment of adenomyosis","volume":"193","author":"Dason","year":"2021","journal-title":"CMAJ"},{"key":"R2-2-20240830","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/S0140-6736(95)91387-4","article-title":"Uterine junctional zone: Function and disease","volume":"346","author":"Brosens","year":"1995","journal-title":"Lancet"},{"key":"R3-2-20240830","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12958-016-0185-6","article-title":"Adenomyosis in infertile women: Prevalence and the role of 3D ultrasound as a marker of severity of the disease","volume":"14","author":"Puente","year":"2016","journal-title":"Reprod Biol Endocrinol"},{"key":"R4-2-20240830","doi-asserted-by":"crossref","first-page":"146","DOI":"10.23736\/S0026-4784.18.04318-6","article-title":"Effects of adenomyosis on obstetric outcomes","volume":"71","author":"Cozzolino","year":"2019","journal-title":"Minerva Ginecol"},{"key":"R5-2-20240830","first-page":"63","article-title":"Reproductive outcomes after hysteroscopic metroplasty for women with dysmorphic uterus and recurrent implantation failure","volume":"10","author":"Ferro","year":"2018","journal-title":"Facts Views Vis Obgyn"},{"key":"R6-2-20240830","first-page":"6832685","article-title":"The investigation and management of adenomyosis in women who wish to improve or preserve fertility","volume":"2018","author":"Li","year":"2018","journal-title":"Biomed Res Int"},{"key":"R7-2-20240830","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1111\/jog.13917","article-title":"Adverse symptoms during short-term use of ulipristal acetate in women with uterine myomas and\/or adenomyosis","volume":"45","author":"Hong","year":"2019","journal-title":"J Obstet Gynaecol Res"},{"key":"R8-2-20240830","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1080\/14740338.2016.1248943","article-title":"Safety of treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate","volume":"15","author":"Donnez","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"R9-2-20240830","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1111\/bcp.14708","article-title":"Risk-efficacy balance of ulipristal acetate compared to surgical alternatives","volume":"87","author":"Middelkoop","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"R10-2-20240830","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1517\/14656566.2014.953055","article-title":"An update on the pharmacological management of adenomyosis","volume":"15","author":"Streuli","year":"2014","journal-title":"Expert Opin Pharmacother"},{"key":"R11-2-20240830","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.tjog.2014.04.024","article-title":"Medical treatment for adenomyosis and\/or adenomyoma","volume":"53","author":"Tsui","year":"2014","journal-title":"Taiwan J Obstet Gynecol"},{"key":"R12-2-20240830","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/j.jmig.2018.04.002","article-title":"Ulipristal acetate improves clinical symptoms in women with adenomyosis and uterine myomas","volume":"25","author":"Gracia","year":"2018","journal-title":"J Minim Invasive Gynecol"},{"key":"R13-2-20240830","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/09513590.2018.1505846","article-title":"Ulipristal acetate therapy increases ultrasound features of adenomyosis: A good treatment given in an erroneous diagnosis of uterine fibroids","volume":"35","author":"Conway","year":"2019","journal-title":"Gynecol Endocrinol"},{"key":"R14-2-20240830","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.rbmo.2020.11.012","article-title":"Progression of adenomyosis magnetic resonance imaging features under ulipristal acetate for symptomatic fibroids","volume":"42","author":"Calderon","year":"2021","journal-title":"Reprod Biomed Online"},{"key":"R15-2-20240830","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.fertnstert.2020.04.017","article-title":"Gonadotropin-releasing hormone antagonist (linzagolix): A new therapy for uterine adenomyosis","volume":"114","author":"Donnez","year":"2020","journal-title":"Fertil Steril"},{"key":"R16-2-20240830","doi-asserted-by":"crossref","first-page":"101978","DOI":"10.1016\/j.jogoh.2020.101978","article-title":"Ulipristal acetate use in adenomyosis: A randomized controlled trial","volume":"50","author":"Capmas","year":"2021","journal-title":"J Gynecol Obstet Hum Reprod"}],"container-title":["Gynecology and Minimally Invasive Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/gmit.gmit_95_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:16:56Z","timestamp":1787757416000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/gmit.gmit_95_21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/gmit.gmit_95_21","relation":{},"ISSN":["2213-3070"],"issn-type":[{"value":"2213-3070","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]}}}